These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29127255)

  • 1. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
    Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM
    Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of phospho-specific Rab protein antibodies to monitor
    Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR
    Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.
    Fan Y; Nirujogi RS; Garrido A; Ruiz-Martínez J; Bergareche-Yarza A; Mondragón-Rezola E; Vinagre-Aragón A; Croitoru I; Gorostidi Pagola A; Paternain Markinez L; Alcalay R; Hickman RA; Düring J; Gomes S; Pratuseviciute N; Padmanabhan S; Valldeoriola F; Pérez Sisqués L; Malagelada C; Ximelis T; Molina Porcel L; Martí MJ; Tolosa E; Alessi DR; Sammler EM
    Acta Neuropathol; 2021 Sep; 142(3):475-494. PubMed ID: 34125248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation.
    Fan Y; Tonelli F; Padmanabhan S; Baptista MAS; Riley L; Smith D; Marras C; Howden A; Alessi DR; Sammler E
    J Vis Exp; 2020 Mar; (157):. PubMed ID: 32250352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease.
    Karayel Ö; Tonelli F; Virreira Winter S; Geyer PE; Fan Y; Sammler EM; Alessi DR; Steger M; Mann M
    Mol Cell Proteomics; 2020 Sep; 19(9):1546-1560. PubMed ID: 32601174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain.
    Singh V; Menard MA; Serrano GE; Beach TG; Zhao HT; Riley-DiPaolo A; Subrahmanian N; LaVoie MJ; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2023 Dec; 11(1):201. PubMed ID: 38110990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.
    Thirstrup K; Dächsel JC; Oppermann FS; Williamson DS; Smith GP; Fog K; Christensen KV
    Sci Rep; 2017 Aug; 7(1):10300. PubMed ID: 28860483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
    Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
    Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
    Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
    Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease.
    Eyers PA
    Biochem J; 2018 Jan; 475(1):185-189. PubMed ID: 29305429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.
    Ito G; Katsemonova K; Tonelli F; Lis P; Baptista MA; Shpiro N; Duddy G; Wilson S; Ho PW; Ho SL; Reith AD; Alessi DR
    Biochem J; 2016 Sep; 473(17):2671-85. PubMed ID: 27474410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites.
    Nirujogi RS; Tonelli F; Taylor M; Lis P; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2021 Jan; 478(2):299-326. PubMed ID: 33367571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Up with the LRRK': a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement.
    Eyers PA
    Biochem J; 2016 Sep; 473(18):2757-62. PubMed ID: 27621483
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Petridi S; Middleton CA; Ugbode C; Fellgett A; Covill L; Elliott CJH
    G3 (Bethesda); 2020 Jun; 10(6):1903-1914. PubMed ID: 32321836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
    Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.